As the PD-1/PD-L1 axis is a target of immunotherapy and antibodies against PD-1 are approved for the treatment of cervical cancers [24] as well as considered for the treatment of vulvar cancers [25, 26], we evaluated PD-L1 expression on CTCs during therapy. The gene discussed is CD274; the disease is cervical carcinoma.